Patents by Inventor Sandra Rios

Sandra Rios has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purification process for removal of tyrosine sulfation antibody variants; purified compositions
    Patent number: 12162938
    Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Jia Zhao, Sandra Rios, Svetlana Dukleska Schussler
  • Purification Process for Removal of Tyrosine Sulfation Antibody Variants; Purified Compositions
    Publication number: 20200123251
    Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 23, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jia Zhao, Sandra Rios, Svetlana Dukleska Schussler
  • N-GLYCOSYLATED INSULIN ANALOGUES
    Publication number: 20160289290
    Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1-9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(1-4)GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of NANA(1-4)Gal(1-4)GlcNAc(1-4)Man3GlcNAc2.
    Type: Application
    Filed: January 14, 2016
    Publication date: October 6, 2016
    Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
  • N-GLYCOSYLATED INSULIN ANALOGUES
    Publication number: 20140235537
    Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1—9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1—4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(j.
    Type: Application
    Filed: August 3, 2012
    Publication date: August 21, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
  • GRANULOCYTE-COLONY STIMULATING FACTOR PRODUCED IN GLYCOENGINEERED PICHIA PASTORIS
    Publication number: 20120213728
    Abstract: Compositions comprising granulocyte-colony stimulating factor (GCSF) produced in a strain of Pichia pastoris glycoengineered to produce a GCSF wherein greater than 18% of the molecules comprise an 0-glycan with one mannose per (0-glycan is described. In particular aspects, the GCSF is PEGylated at the JV-terminus.
    Type: Application
    Filed: October 25, 2010
    Publication date: August 23, 2012
    Applicant: MERCK
    Inventors: Michael Meehl, Sandra Rios, Sujatha Gomathinayagam, Huijuan Li, Piotr Bobrowicz
  • Glycosylated glucocerebrosidase expression in fungal hosts
    Publication number: 20050265988
    Abstract: A recombinant fungal host cell producing recombinant glucocerebrosidase is provided. A functional recombinant glucocerebrosidase produced in recombinant fungal host cells is also provided. Methods for producing and isolating functional recombinant glucocerebrosidase from fungal hosts are also provided.
    Type: Application
    Filed: March 18, 2005
    Publication date: December 1, 2005
    Inventors: Byung-Kwon Choi, Sandra Rios, Stefan Wildt, Tillman Gerngross